Due to the increasing evidence in various disease states and the suggested mechanisms of action, it seems reasonable to explore the potential of SGLT2 inhibition in improving outcomes for patients with acute myocardial infarction if administered promptly after the presentation. The gene discussed is SLC5A2; the disease is acute myocardial infarction.